Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EMA Revises Guidance On Risk Management Plans To Address Industry ‘Misunderstandings’

Executive Summary

The European Medicines Agency is finalizing changes to its eagerly-awaited guidance on risk management plans, which aims to simplify the submission and maintenance of RMPs by drug companies. The EMA has fine-tuned the document to address some misunderstandings within the industry and is currently deciding on the transition plans for implementing the new requirements.


Related Content

Companies Use Revised EU Risk Management Plan Template Ahead Of Mandatory Deadline
EU Generic Industry Group Looks At Radical Options To Simplify Pharmacovigilance Tasks
EFPIA Picks Holes With EMA's Revised Guidance On Risk Management Plans
EMA Proposes Significant Changes To Guidance On Risk Management Plans And Template
It shouldn't be this way: Generic drug firms air frustration over EU risk management plans





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts